Hong Kong
· Delayed Price · Currency is HKD Qyuns Therapeutics Company Description
Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, focuses on the research and development of biologic therapies for autoimmune and allergic diseases in the People’s Republic of China.
The company’s lead product candidates include QX002N, an interleukin (IL)-17A inhibitor in Phase III clinical trial for the treatment of ankylosing spondylitis and lupus nephritis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Rα, which has completed Phase II clinical trial, to treat atopic dermatitis, prurigo nodularis, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria (CSU), asthma, and chronic obstructive pulmonary disease (COPD).
It also develops QX001S, an IL-12/IL-23p40 inhibitor in Phase III clinical trial for the treatment of psoriasis (Ps), and ulcerative colitis/Crohn’s disease (CD); QX004N an IL-23p19 inhibitor in Phase II clinical trial to treat Ps and CD; QX006N, an IFNAR1-targeting mAb, which is in Phase Ib clinical trial, for the treatment of systemic lupus erythematosus; and QX008N, a humanized IgG1 mAb targeting thymic stromal lymphopoietin in Phase Ib clinical trial to treat moderate-to-severe asthma and COPD.
In addition, the company is developing QX007N targeting IL-33 for the treatment of COPD and asthma; QX013N targeting c-kit to treat CSU; and QX010N, an IL-31R inhibitor for the treatment of pruritus.
Further, it researches, develops, and produces pharmaceutical products; and provides technical consultation services.
Qyuns Therapeutics Co., Ltd. was incorporated in 2015 and is headquartered in Taizhou, China.
| Country | China |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 331 |
| CEO | Jiwan Qiu |
Contact Details
Address: Building 1 Taizhou China | |
| Phone | 86 523 8027 6311 |
| Website | qyuns.net |
Stock Details
| Ticker Symbol | 2509 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE1000069W9 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jiwan Qiu | GM, Chief Executive Officer and Chairman of the Board |
| Yiliang Wu | Executive Director and Executive Deputy GM of Cellularforce |
| Weidong Lin | Deputy GM and Executive Director |
| Dr. Jianwei Li | Deputy GM and Chief Operating Officer |
| Shenglong Wu | Deputy GM and Chief Business Officer |
| Min Fang | Deputy General Manager |
| Yanbao Hu | Board Secretary and Joint Company Secretary |
| King Yin Tang | Joint Company Secretary |